Aethlon Medical to Release First Quarter Financial Results and Host Conference Call on August 13, 2026
Aethlon Medical, Inc. (Nasdaq: AEMD) said it will release fiscal first-quarter results for the period ended June 30, 2026 on Aug. 13, 2026 at 4:15 p.m. ET, followed by a conference call at 4:30 p.m. ET. A replay will be available after the call through Sept. 13, 2026.
How this was made
The 30-second read
Why it matters
The primary tradable element is the fixed earnings timeline, which can concentrate options and liquidity around the release and Q&A. The PR itself does not include new efficacy, regulatory, or financial figures.
Market read
This sets a concrete earnings-call calendar for AEMD, creating an event window for volatility and positioning ahead of the Q1 financial release.
What to watch
Volatility may be driven less by headline revenue and more by cash burn, financing needs, and any incremental regulatory or clinical milestones discussed during the call.
Background
Aethlon Medical is a clinical-stage therapeutic company developing the Hemopurifier, an FDA Breakthrough Device-designated immunotherapeutic device.
Ticker impact
Aethlon Medical schedules fiscal Q1 results for Aug 13, 2026 at 4:15 p.m. ET and a call at 4:30 p.m. ET.
Moderate event-driven volatility into Aug 13, with direction dependent on Q1 financials and any updates on Hemopurifier regulatory or clinical progress.
The release discloses timing for results and the conference call but provides no new financial numbers or trial/regulatory outcomes in the text itself.
Market effects
Adds a near-term data point for clinical-stage medical device and immunotherapy names, but no sector-wide read-across is provided.
Limited, as the disclosure is company-specific and not tied to broader macro or regional catalysts.
Low, since the event is a US-listed microcap earnings timing update with no international deal or regulatory action mentioned.
Counterpoint
Traders may treat this as routine scheduling and fade positioning until the actual Q1 numbers and any Hemopurifier progress updates are released.
Key entities
- companyAethlon Medical, Inc.
Nasdaq-listed medical therapeutic company announcing timing for fiscal Q1 results and a conference call.
- productHemopurifier
Clinical-stage immunotherapeutic device with FDA Breakthrough Device designation, referenced as the company’s core pipeline.
